Landmark Research Studies
completed

To evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/ hydrochlorothiazide, used alone or together can reduce the risk of heart attack, stroke and their sequelae in people without known heart disease at average risk. The largest ongoing trial evaluating the polypill concept in primary prevention, expected to have a significant impact on primary prevention strategies globally.

Co-Primary endpoints were: 1) The composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. 2) The composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure and arterial revascularizations.

Secondary endpoints were: total mortality and the components of the co-primary endpoints. Additional endpoints include progression of renal disease, new diagnosis of diabetes, cognitive function and erectile dysfunction in men. All primary and secondary endpoints are adjudicated.

Study Type

Interventional - Drug

Study Design

Randomized, double-blind, placebo control, factorial assignment

NO. of Countries

21

NO. of Sites

229

NO. of Participants

12705

Study Period

2007-2015

Sponsor

PHRI

AstraZeneca

Back To Top